Aarti Pharmalabs (BOM:543748) EBIT per Share : ₹36.90 (TTM As of Sep. 2024)

View and export this data going back to 2023. Start your Free Trial

What is Aarti Pharmalabs EBIT per Share?

Aarti Pharmalabs's EBIT per Share for the three months ended in Sep. 2024 was ₹8.52. Its EBIT per Share for the trailing twelve months (TTM) ended in Sep. 2024 was ₹36.90.

During the past 12 months, the average EBIT per Share Growth Rate of Aarti Pharmalabs was 19.40% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.

The historical rank and industry rank for Aarti Pharmalabs's EBIT per Share or its related term are showing as below:

BOM:543748's 3-Year EBIT Growth Rate is not ranked ^*
in the Drug Manufacturers industry.
Industry Median: 6.8
* Ranked among companies with meaningful 3-Year EBIT Growth Rate only.

Aarti Pharmalabs's EBIT for the three months ended in Sep. 2024 was ₹773 Mil.

Aarti Pharmalabs EBIT per Share Historical Data

The historical data trend for Aarti Pharmalabs's EBIT per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aarti Pharmalabs EBIT per Share Chart

Aarti Pharmalabs Annual Data

Trend

Mar21

Mar22

Mar23

Mar24

EBIT per Share

17.18

31.10

35.05

Aarti Pharmalabs Quarterly Data
	Mar21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
EBIT per Share	Get a 7-Day Free Trial							7.82	8.64	11.09	8.67	8.52

Aarti Pharmalabs EBIT per Share Calculation

EBIT per Share is the amount of Earnings Before Interest and Taxes (EBIT) per outstanding share of the company's stock.

Earnings Before Interest and Taxes (EBIT) is what the company earns before it expenses interest and taxes.

Aarti Pharmalabs's EBIT per Share for the fiscal year that ended in Mar. 2024 is calculated as

	EBIT per Share		(A: Mar. 2024 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	3177.066	/	90.634
=	35.05

Aarti Pharmalabs's EBIT per Share for the quarter that ended in Sep. 2024 is calculated as

	EBIT per Share		(Q: Sep. 2024 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	772.732	/	90.735
=	8.52

EBIT per Share for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹36.90

Aarti Pharmalabs (BOM:543748) EBIT per Share Explanation

EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.

Aarti Pharmalabs EBIT per Share Related Terms

Thank you for viewing the detailed overview of Aarti Pharmalabs's EBIT per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Aarti Pharmalabs Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Aarti Pharmalabs Ltd (BOM:543748) » Definitions » EBIT per Share

Traded in Other Exchanges

AARTIPHARM:India

Address

Mulund Goregaon Link Road, 2nd floor, 204, Udyog Kshetra, Mulund West, Mumbai, MH, IND, 400080

Website

https://www.aartipharmalabs.com

Aarti Pharmalabs Ltd manufactures pharmaceuticals and nutraceuticals with a footprint. It manufactures Active Pharmaceutical Ingredients (API), pharmaceutical intermediates, and xanthine derivatives in India. It also offers Contract Development and Manufacturing Services (CDMS) for drug substance (NCE, RSM, Intermediates) projects. Geographically, the company generates maximum revenue from its customers located outside India.

Aarti Pharmalabs Headlines

No Headlines